Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.12.18
Views: 124

Dr Alok Khorana - Cleveland Clinic, Cleveland, USA

Dr Alok Khorana speaks to ecancer at ASH 2018 about results from the CASSINI trial.

He explains that for the trial a risk assessment score was designed to look at thrombotic events in cancer patients and high risk patients were tested to see if rivaroxaban reduced the risk without increasing the risk of bleeding.

Dr Khorana states that rivaroxaban can be taken by patients with a high risk with bleeding incidents recorded to be low.

Read more about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation